Antimicrobial Agents and Chemotherapy

Article	Citations
Therapeutic efficacy of pyronaridine-artesunate (Pyramax) in treating Plasmodium vivax malaria in the central highlands of Vietnam	193
Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19	178
Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa	166
In vitro and in vivo efficacy of the amiodarone and praziquantel combination against the blood fluke Schistosoma mansoni	132
Case Commentary: A herculean effort for Mycobacterium heraklionense —localized azithromycin bead pharmacokinetics	120
Editorial Board	111
Efficacy of ivermectin and its metabolites against Plasmodium falciparum liver stages in primary human hepatocytes	98
Molecular and Kinetic Characterization of MOX-9, a Plasmid-Mediated Enzyme Representative of a Novel Sublineage of MOX-Type Class C β-Lactamases	92
Killing Two Birds with One Stone: Discovery of Dual Inhibitors of Oxygen and Fumarate Respiration in Zoonotic Parasite, Echinococcus multilocularis	79
Inhibition of AMPK activation in Echinococcus granulosus sensu stricto limits the parasite’s glucose metabolism and survival	76
Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis	70
Prevalence and dynamics of antimalarial drug resistance mutations among the Plasmodium falciparum isolates in TAK Province, Thailand, during the period of 1998–2001	69
Integrating Pharmacokinetic–Pharmacodynamic Modeling and Physiologically Based Pharmacokinetic Modeling to Optimize Human Dose Predictions for Plasmodium falciparum Malaria: a Chloroquine Case Study	66
A Cephalosporin-Tripodalamine Conjugate Inhibits Metallo-β-Lactamase with High Efficacy and Low Toxicity	66
Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis	64
Antimicrobial Agents and Chemotherapy Launches a New Section Focused on Innovative Antimicrobial Stewardship Studies	57
Establishment of epidemiological cutoff values for clinically relevant Sporothrix species using CLSI-broth microdilution	56
α-Mangostin Exhibits a Therapeutic Effect on Spinal Cystic Echinococcosis by Affecting Glutamine Metabolism	53
Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial	48
Use of frozen native feces for fecal microbiota transplantation in recurrent Clostridioides difficile infection: a simple way to improve the efficiency of donor feces pr	47
Single-ascending and multiple-ascending dose study of the pharmacokinetics, safety, and tolerability of BV100 (rifabutin for infusion) in healthy volunteers	45
Neutralizing Antibody Given after Paralysis Onset Reduces the Severity of Paralysis Compared to Nonspecific Antibody-Treated Controls in a Mouse Model of EV-D68-Associated Acute Flaccid Myelitis	45
High-Resolution Bacterial Cytological Profiling Reveals Intrapopulation Morphological Variations upon Antibiotic Exposure	44
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing	44
Correction for Nelson et al., “Pbp4 provides transpeptidase activity to the FtsW-PbpB peptidoglycan synthase to drive cephalosporin resistance in Enterococcus faecalis	44

Successful addition of topical antibiotic treatment after surgery in treatment-refractory nontuberculous mycobacterial skin and soft tissue infections	42
Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobac	42
Simulated endocardial vegetation model highlights the complexity of high-inoculum infections among β-lactamase-producing organisms	42
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis	41
Characterization of a Carbapenem-Resistant BKC-1-Producing Clinical Isolate Belonging to the Pseudomonas putida Group from Brazil	41
Comparative pharmacodynamics and dose optimization of liposomal amphotericin B against Candida species in an in vitro pharmacokinetic/phar	40
Genetic interaction analysis of Candida glabrata transcription factors CST6 and UPC2A in the regulation of	40
Emergence of KPC-31, a KPC-3 Variant Associated with Ceftazidime-Avibactam Resistance, in an Extensively Drug-Resistant ST235 Pseudomonas aeruginosa Clinical Isolate	39
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains	39
Geo-classification of drug-resistant travel-associated Plasmodium falciparum using Pfs47 and Pfcpmp gene se	39
Pharmacokinetic-pharmacodynamic target attainment with continuous infusion piperacillin in patients admitted to the ICU with hospital-acquired pneumonia	38
Mutations in the proximal binding site and F-loop of AdeJ confer resistance to efflux pump inhibitors	37
Correction for Canfield et al., “Lytic Bacteriophages Facilitate Antibiotic Sensitization of Enterococcus faecium”	37
A survey of patient practices regarding leftover antibiotics reveals a potential source of antibiotic overuse	37
Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease	36
Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefidero	36
In vitro activity of ibrexafungerp against clinically relevant echinocandin-resistant Candida strains	35
Insights into current coccidioidomycosis therapeutic pathways	35
No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate	35
Population Pharmacokinetics and Dosage Optimization of Vancomycin in Pediatric Patients with Skin and Soft Tissue Infections, Bone, and Joint Infections	34
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii	34
ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten	34
Epidemiology and impact of methicillin-sensitive Staphylococcus aureus with β-lactam antibiotic inoculum effects in adults with cystic fibrosis	33
Analysis of clinical Candida parapsilosis isolates reveals copy number variation in key fluconazole resistance genes	33
Pharmacokinetic–pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid	33
Loss of the ferripyochelin receptor FptA drives reduced cefiderocol susceptibility and impairs fitness in Pseudomonas aeruginosa PA14	33
Omadacycline powder for research procured from unauthorized commercial vendors may be impure and/or unstable	32
Towards precision dosing of vancomycin in patients with allogeneic hematopoietic stem cell transplantation: a comparison of published population pharmacokinetic models	32
A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model	32
The metabolic slowdown caused by the deletion of pspA accelerates protein aggregation during stationary phase facilitating antibiotic persistence	31
Triple antimicrobial combinations with potent synergistic activity against M. abscessus	31
In Vitro Activity of Ertapenem against Neisseria gonorrhoeae Clinical Isolates with Decreased Susceptibility or Resistance to Extended-Spectrum Cephalosporins in Nanjing, Ch	31
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia	30
Spread of dual-class drug-resistant Mycoplasma genitalium in Tokyo, Japan, 2023–2025	30
XerC Is Required for the Repair of Antibiotic- and Immune-Mediated DNA Damage in Staphylococcus aureus	30
Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children	30
Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients	30
Polyimidazolium Protects against an Invasive Clinical Isolate of Salmonella Typhimurium	29
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa	29
Phenotypic Profiling of Macrocyclic Lactones on Parasitic Schistosoma Flatworms	29
Double carbapenemases in Klebsiella pneumoniae blood isolates: dissemination in a single medical center via multiple plasmids and a variety of highly efficient clones	29
Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an In Vitro Pharmacodynamic Model Using Humanized Dosing Simulations	29
Bridging clinical and environmental reservoirs: antimicrobial resistance in the emerging pathogen Shewanella algae	29
Gentamicin and clindamycin antibiotic-eluting depot technology eradicates S. aureus in an implant-associated osteomyelitis pig model without systemic antibiotics	29
Can letrozole be repurposed for the treatment of visceral leishmaniasis?	28
Bacteriophage treatment is effective against carbapenem-resistant Klebsiella pneumoniae (KPC) in a neutropenic murine model of gastrointestinal translocation and renal i	28
Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics	28
The heme A synthase Cox15, as a target of redox-active 3-benzylmenadiones with antiparasitic activity	28
A rational approach to discovering new persister control agents	28
Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis	28

Selective antimicrobial photodynamic therapy of clinical isolates from patients with infected diabetic foot ulcers using a small cationic chlorin	28
Characterization of Extended-Spectrum β-Lactamase-Producing Shigella sonnei in Spain: Expanding the Geographic Distribution of Sequence Type 152/CTX-M-27 Clone	28
Retraction for Kim et al., “Complete Sequence of bla KPC-2 -Harboring Plasmid with a Mosaic of IncN1- and IncN3-Type Plasm	27
T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren	27
Erratum for Ranjbarian et al., “9-(2'-Deoxy-2'-Fluoro-β- d -Arabinofuranosyl) Adenine Is a Potent Antitrypanosomal Adenosine Analogue That Circumvent	26
Mutation of PA4292 in Pseudomonas aeruginosa Increases β-Lactam Resistance through Upregulating Pyocyanin Production	26
In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022)	26
Atazanavir Resensitizes Candida auris to Azoles	26
Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants	25
Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales	25
Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible	25
Pharmacokinetics of Voriconazole in Peritoneal Fluid of Critically Ill Patients	25
Long-range PCRs and next-generation sequencing to detect cytomegalovirus drug resistance-associated mutations	25
Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro	25
In vitro efficacy of humanized regimen of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneu	25
An immune-mediated effect of the antibiotic cefiderocol on LPS-induced acute lung injury	24
In vivo dose response and efficacy of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus	24
Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study	24
Comparison of lumefantrine, mefloquine, and piperaquine concentrations between capillary plasma and venous plasma samples in pregnant women with uncomplicated falciparum and vivax malaria	24
Impact of 16S rRNA Single Nucleotide Polymorphisms on Mycoplasma genitalium Organism Load with Doxycycline Treatment	24
Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria among Children in Western Kenya, 2016 to 2017	24
Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against Plasmodium vivax in Australian Defence Force personnel	24
Investigating and Treating a Corneal Ulcer Due to Extensively Drug-Resistant Pseudomonas aeruginosa	24
Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants	24
Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability	24
Evolution of Fluconazole Resistance Mechanisms and Clonal Types of Candida parapsilosis Isolates from a Tertiary Care Hospital in South Korea	24
Fractional curative killing of pyronaridine or artesunate combinations with tafenoquine, 4-aminoquinolines, or azithromycin in a murine malaria-luciferase model	24
Model-based quantification of immune response and anti-staphylococcal activity of afabicin in immunocompetent mouse thigh infections to enable predictions of clinical efficacy	24
Metabolic mechanism and pharmacological study of albendazole in secondary hepatic alveolar echinococcosis (HAE) model rats	23
Effect of malate on the activity of ciprofloxacin against Pseudomonas aeruginosa in different in vivo and in vivo	23
Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mut	23
Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against Cryptosporidium parvum	23
In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae	23
Synergistic effects of Cyp51 isozyme-specific azole antifungal agents on fungi with multiple cyp51 isozyme genes	23
Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections	23
Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients	23
Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis	23
Intrinsic Antibacterial Activity of Xeruborbactam In Vitro : Assessing Spectrum and Mode of Action	23
The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug–drug interaction study	23
Pseudomonas aeruginosa Phosphate Transporter PitA (PA4292) Controls Susceptibility to Aminoglycoside Antibiotics by Regulating the Proton Motive Force	22
Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection	22
Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis	22
Retrospective validation study of a machine learning-based software for empirical and organism-targeted antibiotic therapy selection	22
First Isolation of Vancomycin-Resistant Enterococcus faecium Carrying Plasmid-Borne vanD1	22
Successful use of olorofim for the treatment of Lomentospora prolificans knee tendonitis, synovitis, and concomitant osteomyelitis in an immunocompetent	22
In vitro activity of taurolidine against clinical Candida auris isolates: relevance to catheter-related bloodstream infections	22
The Azithromycin Pro-Drug CSY5669 Boosts Bacterial Killing While Attenuating Lung Inflammation Associated with Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus	22
In Vitro Activity and Clinical Efficacy of Faropenem against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella p	21
Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects	21
Clinical and genomic determinants associated with emergent ceftazidime–avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli	21
H 2 inhalation therapy in patients with moderate COVID-19 (H 2 COVID): a prospective ascending-dose phase I clinical trial	21
Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection	21
Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets	21
In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals	21
Evolution toward extremely high imipenem resistance in Mycobacterium abscessus outbreak strains	20
Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections	20
Preparation of Decoquinate Solid Dispersion by Hot-Melt Extrusion as an Oral Dosage Form Targeting Liver-Stage Plasmodium Infection	20
Efficacy and in vitro pharmacological assessment of novel N -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors	20
Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae	20
Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model	20
Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact	20
Candida parapsilosis and echinocandins: should the clinical laboratory drop anidulafungin Etest from the susceptibility testing panel?	20
Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial	20
First Detection of Mycobacterium tuberculosis Clinical Isolates Harboring I491F Borderline Resistance rpoB Mutation in Myanmar	20
Drug-resistant clinical Candida responded to 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in vitro	20
Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients	20
Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes	20
Mutations in genes lpxL1 , bamA , and pmrB impair the susceptibility of cystic fibrosis strains of	20
A Plasmodium falciparum RING Finger E3 Ubiquitin Ligase Modifies the Roles of PfMDR1 and PfCRT in Parasite Drug Responses	20
Efficacy and safety of early antibiotic de-escalation in febrile neutropenia for patients with hematologic malignancy: a systematic review and meta-analysis	20
Differences in β-lactamase activity and carbapenem resistance among the Bacillus cereus group	20
A propidium iodide-based in vitro screen of the “Bug Box” against Babesia duncani reveals potent inhibitor	19
Escherichia coli ST1193: Following in the Footsteps of E. coli ST131	19
Phenazine-1 carboxylic acid of Pseudomonas aeruginosa induces the expression of Staphylococcus aureus Tet38 MDR efflux pump and mediates r	19
Polymorphisms in the type A blaZ gene as determinants of the cefazolin inoculum effect in Staphylococcus aureus	19
The antimycotic 5-fluorocytosine is a virulence inhibitor of uropathogenic Escherichia coli and eradicates biofilm-embedded bacteria synergizing with β-l	19
Mycobacterium heraklionense hand tenosynovitis—a case description of a three-year treatment course and perioperative measurement of azithromycin target tissue concentrations	19
Bisacodyl Limits Chikungunya Virus Replication In Vitro and Is Broadly Antiviral	19
The NaHCO 3 -Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus (MRSA) Is Influenced by mecA Genotype	19
Mechanistic blockade of Pseudomonas aeruginosa type III secretion by a monoclonal antibody targeting the pore size-determining domain of PcrV	19

Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections	19
Synergistic Effect of the Combination of Deferoxamine and Fluconazole In Vitro and In Vivo against Fluconazole-Resistant Ca	19
Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization	19
Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistant Burkholderia pseudomallei in a murine infection model	19
Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects	18
Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations	18
Comparative in vitro activity of aztreonam–avibactam and aztreonam plus ceftazidime–avibactam against Stenotrophomonas maltophilia	18
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis	18
Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase	18
Emergence of antibiotic-resistant pneumococcal serotypes causing invasive pneumococcal disease in children, Spain	18
Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus In Vitro	18
Evidence that remdesivir treatment reduces viral titers in patients with COVID-19	18
Transposition mechanism of IS Apl1 —the determinant of colistin resistance dissemination	18
Expression of Concern for Angelakis et al., “Abnormal Weight Gain and Gut Microbiota Modifications Are Side Effects of Long-Term Doxycycline and Hydroxychloroquine Treatment”	18
Putative azithromycin resistance mutations in Chlamydia trachomatis are globally distributed but arose before azithromycin was discovered	18
Population pharmacokinetic model and dosing nomogram for daptomycin in adult patients with serious Gram-positive infections: emphasizing the role of loading doses and renal function-based adjustment	18
Identification and characterization of a novel inhibitor of influenza A virus that acts by blocking nucleoprotein oligomerization	18
Immunocompromised patients with persistent SARS-CoV-2 viral shedding ≥8 weeks, clinical outcomes, and virological dynamics: a retrospective multicenter cohort study, 2020–2024	18
Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against Pseudomonas aeruginosa by enhancing membrane potential	18
Genome-wide screen reveals glycerol-induced aminoglycoside potentiation against Staphylococcus aureus via boosting GlpK-initiated energy metabolism	18
Nature of bacitracin resistance in Staphylococcus aureus	18
Bacterial bioluminescence for the real time and in situ monitoring of endoscope disinfection using plasma activated water	18
HOCl-producing electrochemical bandage for treating Pseudomonas aeruginosa -infected murine wounds	18
Characterization of a novel monoclonal antibody candidate that targets bacterial GAPDH and protects neonatal mice from infections caused by Streptococcus pneumoniae	18
Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue	18
Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens	17
Comparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris	17
Seminal plasma concentrations of long-acting cabotegravir in men receiving HIV pre-exposure prophylaxis	17
The Spx stress regulator confers high-level β-lactam resistance and decreases susceptibility to last-line antibiotics in methicillin-resistant Staphylococcus aureus	17
Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis	17
A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections	17
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia	17
Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD	17
Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix in Candida auris ( Candidozyma auris	17
Phase 1, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the safety, tolerability, and pharmacokinetics of intravenous xeruborbactam (QPX7728) in healthy adu	17
Phenotypic and Genomic Characterization of ST133 Siderophore-Encoding Extensively Drug-Resistant Enterobacter hormaechei	17
Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates	17
Retraction for Shin et al., “ bla NDM-5 -Bearing IncFII-Type Plasmids of Klebsiella pneumoniae Sequence Type 147 Transmitt	17
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis	17
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis	17
Antibiotics do not induce expression of acrAB directly but via a RamA-dependent pathway	17
Antimalarial activity of cecropin antimicrobial peptides derived from Anopheles mosquitoes	17
Genomic Screening of Antimicrobial Resistance Markers in UK and US Campylobacter Isolates Highlights Stability of Resistance over an 18-Year Period	17
Remdesivir treatment does not reduce viral titers in patients with COVID-19	17
Erratum for Randell et al., “Opportunistic dried blood spot sampling validates and optimizes a pediatric population pharmacokinetic model of metronidazole”	17
Synergistic activity of rifampicin and polymyxin B against intracellular Gram-negative ESKAPE pathogens involves bacterial membrane alterations and enhanced oxidative damages	16
Reply to Datta, “Is static or cidal antibiotic falsifiable?”	16
Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis	16
Second Correction for Huang et al., “ In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Anti	16
In vitro activity of sanitizers against mono- and polymicrobial biofilms of C. parapsilosis and S. aureus	16
A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis	16
Real-time measurements of ATP dynamics via ATeams in Plasmodium falciparum reveal drug-class-specific response patterns	16
Limited Sampling Strategies to Predict Ganciclovir Exposure after Valganciclovir Administration and to Reduce Monitoring Constraints in Renal Transplant Children	16
Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy	16
Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei	16
Vitamin C enhances corneal fungal infection treatment in mice via chemotaxis and anti-inflammation	16
Model for Evaluating Antimicrobial Therapy To Prevent Life-Threatening Bacterial Infections following Exposure to a Medically Significant Radiation Dose	16
Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype	16
Multidimensional assessment of in-host fitness costs of echinocandin resistance in the opportunistic fungal pathogen Candida glabrata reveals the niche-s	16
In vivo selection of CMY-219 conferring resistance to ceftazidime-avibactam in an OXA-484-producing E. coli ST410	16
Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas	16
Plasmid-encoded VCC-1 β-lactamase in a clinical isolate of Aeromonas caviae	16
Impact of Vancomycin Loading Doses and Dose Escalation on Glomerular Function and Kidney Injury Biomarkers in a Translational Rat Model	15
Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide	15
A Novel Oral GyrB/ParE Dual Binding Inhibitor Effective against Multidrug-Resistant Neisseria gonorrhoeae and Other High-Threat Pathogens	15
The microbiome-restorative potential of ibezapolstat for the treatment of Clostridioides difficile infection is predicted through variant PolC-type DNA polymerase III in	15
Exploration of novel mechanisms of azole resistance in Candida auris	15
Plasmodium falciparum GCN5 plays a key role in regulating artemisinin resistance-related stress responses	15
Evolution of beta-lactam resistance causes fitness reductions and several cases of collateral sensitivities in the human pathogen Haemophilus influenzae	15
Evaluation of a Bayesian hierarchical pharmacokinetic–pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs	15
Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment	15
Erratum for Brown-Elliott and Wallace, “ In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria”	15
Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)	15
Emergence of Tn 1999.7 , a New Transposon in bla OXA-48 -Harboring Plasmids Associated with Increased Plasmid Stabi	15
Restoration of daptomycin sensitivity with adjunctive cefazolin is associated with C-terminal MprF mutations in MRSA bacteremia isolates	15
Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV	15
A One Health Genomic Investigation of Gentamicin Resistance in Escherichia coli from Human and Chicken Sources in Canada, 2014 to 2017	15
Genomic insights into ceftazidime resistance in Burkholderia pseudomallei : discovery of A172T mutation and palindromic GC-rich repeat sequences facilita	15
Resistance to Fluconazole of Candida albicans in Vaginal Isolates: a 10-Year Study in a Clinical Referral Center	15
What makes Candida auris pan-drug resistant? Integrative insights from genomic, transcriptomic, and phenomic analysis of clinical strains resistant to all four major cla	15
Preclinical Data on the Gardnerella -Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal an	15
Oral administration of a 2-aminopyrimidine robenidine analogue (NCL195) significantly reduces Staphylococcus aureus infection and reduces Escherichia coli	15
Whole-body distribution of three Pseudomonas phages characterized by a translational physiologically based pharmacokinetic model	14
Genomic Insights into CRISPR-Harboring Plasmids in the Klebsiella Genus: Distribution, Backbone Structures, Antibiotic Resistance, and Virulence Determinant Profiles	14
Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin	14
Exploring the links between SOS response, mutagenesis, and resistance during the recovery period	14
Limited predictive power of known resistance genes for phenotypic drug resistance in clinical Mycobacterium abscessus complex from Beijing in China	14
Benzoxaborole-modified azithromycins inhibit translation without inducing ermC expression	14
Application of machine-learning models to predict the ganciclovir and valganciclovir exposure in children using a limited sampling strategy	14
Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials	14
Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis	14
Inhibition of efflux pumps by FDA-approved drugs oxiconazole and sertaconazole restores antibiotic susceptibility in multidrug-resistant S. aureus	14
Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study	14
Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection	14
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro	14